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There are many cause of cholinesterase deficiency, including drugs, liver disease, chronic anemia, malignant states, 
cardiac failure, severe acute infection, surgical shock, severe burn, collagen disease and vasculitis syndromes.   
Vasculitis syndromes are relatively rare, and among them, Churg-Strauss syndrome (CSS) is even rarer.  We report 
here on a case of a patient with CSS who underwent endoscopic sinus surgery under general anesthesia.  (Korean J 
Anesthesiol 2010; 59: 49-52)
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CC
    Churg-Strauss syndrome (CSS) is an uncommon disease that 
is characterized by allergic rhinitis, asthma and eosinophilia, 
which is an altered blood count [1,2]. The involved organs 
are usually the lung and skin, although any organ system 
can be affected, including the cardiovascular system, the 
gastrointestinal system, the renal system and the central 
nervous system [3].
    Immune complexes are probably involved as the cause of CSS, 
although the exact etiology of this syndrome is unknown [4]. 
The annual incidence rate of CSS per million of the population 
has been estimated to be between 1.3 and 6.8 [5,6].
    Making the diagnosis is difficult because patients with CSS 
have various clinical symptoms and levels of disease progress. 
If treatment is delayed by a late diagnosis, then heart failure 
can be the cause of death. So, a rapid diagnosis and aggressive 
treatment are required to effectively treat patients with CSS.
    Patients with CSS display cholinesterase deficiency, 
hypersensitivity of the airway and multiple organ dysfunctions. 
For this reason, anesthetic management of patients with CSS 
can be difficult. There are not many reports on performing 
anesthesia for patients with CSS. So, we report here on the 
anesthetic management of a patient with CSS and we also 
review the relevant medical literature.
Case Report
    A 34-year-old woman (168 cm tall and weighing 55 kg) 
complained a productive cough, postnasal drip and maxillary 50 www.ekja.org
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pain. The patient was scheduled for endoscopic sinus surgery to 
treat her chronic sinusitis.
    She had a history of bronchial asthma for the previous 2 
years and was on brochodilators (salmeterol 1 puff once a 
day). She was diagnosed with CSS 1 year previously when she 
started complaining of gradually progressive numbness of 
the left 4th and 5th fingers, but the sensory tests were normal 
and the nerve conduction tests showed non-specific finding. 
Her differential WBC count showed peripheral eosinophilia 
and the antineutrophil cytoplasmic autoantibody (ANCA) 
was negative. The skin biopsy showed vasculitis with many 
eosinophils, neutrophils and nuclear debris in the dermis. The 
bronchoalveolar lavage (BAL) fluid showed an increased total 
cell count and the eosinophils were especially dominant. A 
diagnosis of CSS was then made. She was taking oral predni-
solone 10 mg once a day.
    The preoperative routine laboratory values were within 
the normal limits. Mild cough, sputum and rhinorrhea were 
present on the physical examination. The chest X-ray showed 
minimal patchy opacity in the left lower lung zone. The results 
of the pulmonary function tests were within the normal limits 
with a FEV1 of 96%, a FVC of 80% and a FEV1/FVC of 94% of 
the predicted values. Electrocardiography showed inferior 
myocardiac ischemia, but the findings of the echocardiogram 
were within the normal limits. Arterial blood gas analysis on 
room air showed a pH of 7.356, a PaO2 of 76.2 mmHg, a PaCO2 
of 43.2 mmHg and a HCO3 of 23.6 with a SaO2 of 99.0%.
    She was premedicated with intramuscular glycopyrrolate 0.2 
mg before surgery and on the morning of surgery, along with 
overnight fasting. Oral prednisolone was given on the morning 
of surgery. All her medications for asthma were continued.
    In the operating room, routine monitoring was used along 
with a neuromuscular transmission (TOF-Watchr, Organon, 
Ireland) monitor and a continuous arterial pressure monitor 
to determine the degree of muscle relaxation and hypotension 
due to deep anesthesia. General anesthesia was induced with 
propofol 120 mg, inhaled sevoflurane 3-4 vol% and remifentanil 
0.2-0.3 ug/min/kg. The TOF was kept at 90-100% for 3 minutes, 
but after 3 minutes the blood pressure dropped to 70/50 mmHg. 
An intravenous injection of ephedrine (5 mg) was given. The 
blood pressure was stable and the TOF count was 2. Tracheal 
intubation was performed immediately. The anesthesia was 
maintained with sevoflurane 2-3 vol%, remifentanil 0.2-0.3 
ug/min/kg, air and oxygen at FiO2 0.5. Any muscle relaxant was 
not administered during surgery. The TOF was kept at 90-100% 
during surgery. No major problems occurred during surgery.
    At the end of surgery, the remifentanil infusion and sevoflurane 
were stopped and any anticholinesterase agent was not used. 
The breathing sounds were clear and the TOF was kept at 100% 
before extubation, so the tracheal tube was taken out with the 
patient in a deep state of anesthesia. Oxygen was supplemented 
by a face mask till the patient recovered full consciousness and 
self respiration. Her postoperative period was uneventful.
Discussion
    CSS was first described in 1951 by Dr. Jacob Churg and Dr. 
Lotte Strauss as a syndrome consisting of asthma, eosinophilia 
and additional vasculitis of multiple organ systems [1].
    The clinical manifestations of CSS usually have three stages 
[7]. The first phase is called the “allergic” phase and this is 
characterized by allergic inflammation of the nose, the skin 
and the lung. People are often diagnosed with late onset 
asthma during this phase. The second phase is called the 
“hypereosinophilic” phase, which means that there are too 
many eosinophils in the body. This phase is characterized by 
inflammation of the esophagus, stomach or intestine. The third 
phase is the “systemic vasculitis” phase. During this phase there 
is inflammation and damage of the blood vessels; the blood 
vessels in different parts of the body can be damaged. During 
this phase, the patients with CSS may suffer from fever, weight 
loss and a lack of energy. These 3 phases are not necessarily 
contiguous.
    The American College of Rheumatology (ACR) has offered 
criteria that must be fulfilled in order to classify a patient as 
having CSS [8]. In order to be classified as a CSS patient, a 
patient should have at least 4 of the 6 ACR criteria for CSS 
to be diagnosed with a sensitivity of 85% and a specificity of 
99.7%. These criteria are 1) asthma, 2) eosinophilia [>10% on 
the differential WBC count], 3) mononeuropathy, 4) transient 
pulmonary infiltrates on chest X-rays, 5) paranasal sinus 
abnormalities and 6) a biopsy containing a blood vessel with 
extravascular eosinophils. Our patient's asthma, peripheral 
blood eosinophilia, the skin biopsy with an infiltration of 
eosinophils and the chronic sinusitis fulfilled the ACR diagnostic 
criteria.
    CSS commonly responds to prednisone. High doses of oral 
prednisone are initially used in an attempt to get the disease 
into remission as quickly as possibly (e.g., oral prednisone 
40-60 mg/day). After the first month or so, this high dose of 
prednisone is slowly tapered down over the ensuing months 
[9]. Other immunosuppressive drugs such as azathioprine, 
cellcept, cyclophosphamid or methotrexate may be used in 
addition to prednisone. High doses of intravenous steroids, 
and commonly methylprednisolone, maybe useful for those 
patients with severe disease or for those who are unresponsive 
to oral prednisone combined with other immunosuppressive 
medications. 
    The French Vasculitis Study Group has identified five 
prognostic factors, the so-called five-factor score (FFS), 51 www.ekja.org
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for patients with necrotising vasculitis, including CSS [10]. 
These are (1) elevated serum creatinine levels (>1.58 mg/
dl), (2) proteinuria (>1 g per day), (3) gastrointestinal tract 
involvement, (4) cardiomyopathy and (5) central nervous 
system involvement. The presence of one or more factors is 
correlated with a 5-year mortality rate ranging from 25.9-46%, 
whereas an FFS of 0 is correlated with a 5-year mortality rate 
of 11.9% [10]. The prognosis of patients with CSS is not clearly 
known, but a 1 year survival rate of 90% and 5 year survival rate 
of 62% have been reported after treatment with corticosteroid. 
A significant reduction in mortality has been reported after 
treatment [11].
    Most patients with CSS have asthma. So, pulmonary function 
tests are essential as part of the preoperative evaluation of CSS 
patients to assess the risk of perioperative and postoperative 
pulmonary complications. The patient in this case had 
been experiencing asthma for the previous 2 years, but her 
respiratory symptoms were not severe and they were well-
controlled with brochodilators (salmeterol 1 puff once a day), 
and the pulmonary function tests were within the normal limits.
    Surgery requires that a patient have nothing to eat or 
drink for about 6 hours before anesthesia, with an exception 
being medication. Patient with CSS and who have been 
taking corticosteroid for a long time should take their usual 
medication up until the time of surgery. Adrenal insufficiency 
could develop, and CSS patients may require perioperative 
supplemental corticosteroids [12]. The patient in this case took 
oral prednisolone 10 mg on the morning of surgery and there 
was no adverse event during the perioperative period. So, we 
did not medicate her with additional corticosteroid.
    For our case, the anesthesia management during the 
perioperative period was chosen to minimize tracheal activity 
as the patient had asthma. Propofol reduces the intubation-
induced bronchoconstrictive response [13]. Propofol leads to 
bronchodilation in patients with chronic obstructive pulmonary 
disease. The volatile anesthetic agents are bronchodilators that 
relax the airway smooth muscle and decrease the resistance of 
the respiratory system. Some opioids can release histamine, and 
so they can cause bronchospasm. But fentanyl and its analogues 
have an antihistaminergic action and these may be more 
effective than morphine for patients with asthma. Furthermore, 
Groeben reported that the suppression of the cough reflex and 
the deepening of level of anesthesia level that are achieved after 
opioid administration can be helpful in asthmatic patients [14]. 
The anesthetic management was successful in this case by using 
propofol, remifentanil and sevoflurane to induce and maintain 
anesthesia without respiratory complication.
    Taylor and colleagues [15] reported on two patients with 
CSS who were found to have decreased cholinesterase activity 
after abnormal sensitivity to suxamethonium was suspected. 
So, we did not use muscle relaxant as there was no need for 
muscle relaxation for surgery and our patient was adequately 
anesthetized using a volatile anesthetic agent and opioid. A 
deep state of anesthesia was induced and maintained. This 
also reduced any bronchial hyper-reactivity, yet hypotension 
can occur because of deep anesthesia, so a continuous arterial 
pressure monitor was used to detect hypotension early. The 
use of an anticholinesterase agent to reverse muscle relaxation 
can cause bradycardia, increased secretion and brochial hyper-
reactivity, so we did not use an anticholinesterase agent.
    In conclusion, this case was successfully managed using 
general anesthesia following careful preoperative evaluation 
and precise perioperative management. The patients with CSS 
may require intensive care during the course of their disease. 
Muscle relaxant should be used with caution during surgery, 
and successful anesthetic management can be achieved.
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